Azenta, Inc. $AZTA Holdings Lowered by Royce & Associates LP

Royce & Associates LP lowered its stake in Azenta, Inc. (NASDAQ:AZTA – Free Report) by 20.4% during the third quarter, HoldingsChannel.com reports. The firm owned 709,177 shares of the company’s stock after selling 182,242 shares during the period. Royce & Associates LP’s holdings in Azenta were worth $24,743,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Heritage Family Offices LLP bought a new position in shares of Azenta in the 3rd quarter worth $31,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Azenta during the second quarter worth $39,000. State of Wyoming bought a new stake in Azenta in the first quarter valued at about $38,000. Allworth Financial LP bought a new stake in Azenta in the second quarter valued at about $48,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Azenta in the third quarter valued at about $74,000. 99.08% of the stock is currently owned by institutional investors.

Azenta Stock Performance

NASDAQ AZTA opened at $45.65 on Monday. The business has a 50 day simple moving average of $36.52 and a 200 day simple moving average of $28.56. Azenta, Inc. has a 52-week low of $15.93 and a 52-week high of $50.06. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -12.61 and a beta of 1.47.

Azenta (NASDAQ:AZTA – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.11 by $0.17. Azenta had a negative net margin of 26.86% and a positive return on equity of 1.41%. The firm had revenue of $167.09 million for the quarter, compared to the consensus estimate of $160.16 million. On average, analysts predict that Azenta, Inc. will post 0.69 EPS for the current year.

Azenta News Roundup

Here’s some of the latest news about AZTA:

  • Positive Sentiment: Better-than-expected quarterly results helped fuel buying: Azenta reported earnings of $0.28 per share versus analysts’ $0.11 estimate, and revenue of $167.1 million, above the $160.2 million consensus. Shares subsequently reached a 52-week high. Article: Azenta Reaches New 52-Week High Following Better-Than-Expected Earnings
  • Neutral Sentiment: After the sharp post-earnings advance, some investors took profits, contributing to a pullback; this may reflect near-term trading rather than a change in the company’s fundamentals. Article: Azenta Dips as Investors Book Profits
  • Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims tied to allegations that Azenta may have issued materially misleading business information. The investigation is an allegation, not a finding of wrongdoing, but may weigh on sentiment. Article: Rosen Law Firm Investor Notice

Analyst Ratings Changes

AZTA has been the topic of several analyst reports. Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Wall Street Zen upgraded Azenta from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Research assumed coverage on Azenta in a research report on Thursday. They set a “hold” rating for the company. Jefferies Financial Group upped their price target on Azenta from $44.00 to $52.00 and gave the company a “buy” rating in a research note on Wednesday, November 11th. Finally, Needham & Company LLC upped their price target on Azenta from $37.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, November 11th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Azenta has a consensus rating of “Hold” and a consensus target price of $47.60.

Read Our Latest Analysis on Azenta

About Azenta

(Free Report)

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.

Further Reading

Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA – Free Report).

Institutional Ownership by Quarter for Azenta (NASDAQ:AZTA)

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.